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Introduction: Interleukin-6 (IL-6) cytokine signaling is key in Rheumatoid Arthritis (RA) pathophysiology. Blocking
IL-6 receptor (IL6R) has proven to be a highly effective treatment to prevent joint damage. This study was
performed to investigate the association between the genetic variation at IL6R gene and the severity of joint
damage in RA.
Methods: IL6R gene tagging SNPs (n = 5) were genotyped in a discovery group of 527 RA patients from 5
different university hospitals from Spain. For each marker, a linear regression analysis was performed using an
additive model and adjusting for the years of evolution of the disease, autoantibody status, gender and age.
Haplotypes combining the SNPs were also estimated and tested for association with the level of joint destruction.
Using an independent cohort of 705 RA patients from 6 university hospitals we performed a validation study of the
SNPs associated in the discovery phase.
Results: In the discovery group we found a highly significant association between IL6R SNP rs4845618 and the
level of joint destruction in RA (P = 0.0058, Pcorrected = 0.026), and a moderate association with SNP rs4453032
(P = 0.02, Pcorrected = 0.05). The resulting haplotype from both SNPs was more significantly associated with joint
damage (P = 0.0037, Pcorrected = 0.011). Using the validation cohort, we replicated the association between the
two IL-6R SNPs with the degree of joint destruction in RA (P = 0.007 and P = 0.04, meta-analysis P = 0.00011
and P = 0.0021, respectively), and the haplotype association (P = 0.0058, meta-analysis P = 6.64 e-5).
Conclusions: Genetic variation at IL6R gene is associated with joint damage in RA.Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune
disease with an estimated prevalence of ~1 % in the gen-
eral population. RA is characterized by a chronic inflam-
mation of the synovial membrane and the progressive
destruction of the joint cartilage and subchondral bone.
RA is a complex disease in which the interplay between
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The extent of joint damage is a clinically relevant and
highly variable feature among RA patients. Recent stud-
ies have shown that there is a genetic predisposition to
develop higher levels of joint destruction in RA. The
heritability of this clinically relevant trait has been esti-
mated to range from 45 to 60 % [2]. The identification
of the genes and genetic pathways that contribute to in-
crease the risk of joint damage in RA will clearly be of
high value for the future development of prognostic tests
as well as for the design of more efficient therapeutic
approaches.is article is distributed under the terms of the Creative Commons
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
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sociated with RA pathophysiology [3]. IL-6 cytokine is
highly expressed in the inflamed synovial tissue of RA
patients and influences the functionality of multiple cell
types including macrophages and T and B lymphocytes
and osteoclasts [4]. These effects are mediated by the
binding of the cytokine to the IL-6 receptor protein
(IL6R, CD126), which is expressed both on the surface
of the cell membranes as well as in a soluble form. Tar-
geting the cell-bound and soluble IL-6R using monoclo-
nal antibodies has proven to be an efficacious therapy in
RA, significantly reducing structural damage [5]. Conse-
quently, the gene encoding IL-6R is a strong candidate
for association with the level of joint destruction in RA.
We performed a candidate gene study of the associ-
ation of IL-6 receptor gene (IL6R) with the level of joint
damage in RA. To test this hypothesis we identified sin-
gle nucleotide polymorphisms (SNPs) tagging the IL6R
locus and analyzed their association in a discovery co-
hort of RA patients from Spain. Using an independent
cohort of patients, we have subsequently validated the
observed associations.Methods
Study population
All RA patients recruited for this study satisfied the
American College of Rheumatology diagnostic criteria
for RA [6] and had >2 years of follow-up since diagnosis.
Also, all patients were Caucasian with all four grandpar-
ents born in Spain. Two cohorts of patients from different
hospitals in Spain were collected to identify the polymor-
phisms associated with joint destruction (i.e., discovery
phase cohort) and to subsequently validate these SNPs
(i.e., validation phase cohort).
This study was undertaken in compliance with the
Helsinki Declaration. Informed consent was obtained
from all participants, and protocols were reviewed and
approved by local institutional review boards. Ethical
approval was obtained from the Vall d´Hebron Hospital
Ethics Committee.Discovery and validation phase cohorts
In the discovery phase, 527 patients were recruited from
five hospital centers: Hospital Universitario de Asturias,
Hospital Clínic i Provincial de Barcelona, Hospital
Universitari Vall d'Hebron, Hospital Universitario de
Guadalajara, and Hospital del Mar. In the replication
phase, RA patients were collected from six different
hospitals (n = 705): Hospital de San Rafael, Hospital
Universitario La Princesa, INIBIC-Hospital Universitario A
Coruña, Hospital Clínico San Carlos, Hospital Universitari
Germans Trias i Pujol, and Hospital Regional Universitario
de Málaga.Joint damage scoring
Clinical and epidemiological variables were collected from
all patients. Hand and feet radiographic images were ob-
tained from all patients during the inclusion period. Im-
portantly, joint damage was quantified using the same
method in all participating rheumatology departments.
This S-score method is a joint damage scoring system that
captures the level of joint destruction in each patient using
a more practical approach compared with other, more
complex methods [7, 8]. Given the large number of sam-
ples required to analyze the genetic association between
IL6R and joint damage, this score was designed to simplify
the collection of this trait while reducing the time for ac-
quisition of data in the clinical setting. In the S-score
method, six different key areas of the hands and feet are
evaluated and quantified from radiographs—distal radius
(0/1 points), distal ulna (0/1 points), wrist (0/1 points),
metacarpophalangeal joints (0–5 points), interphalangeal
joints (0–5 points), and metatarsophalangeal joints (0–5
points)—for each side and for both hands and feet. In each
of these areas, the presence of an erosion is considered
whenever there is evident loss in the cortical region or loss
in the normal bone shape (i.e., referred to as presence of
remodeling or loss of bone volume), and contributes 1
point to the S-score. For any patient, the maximal S-score
will therefore be 36 (i.e., all areas affected) and the min-
imal score 0 (i.e., no erosions in hands and/or feet).
To confirm the usefulness of the simplified score to
capture joint damage, we first used a sample of RA pa-
tients to compare its correlation with a reference score.
A total of 139 RA patients with >2 years of follow-up
since the diagnosis of the disease were collected, and the
degree of joint damage was measured using the S-score
and the Sharp–van der Heijde Score (SHS) as the refer-
ence score [9]. Although it requires expert training and
a substantial amount of time, the SHS is clearly one of
the most used scores to quantify joint damage in RA. A
highly significant positive correlation (α <0.001) between
both scores was considered a validation of the usefulness
of the S-score to quantify the level of joint destruction
in RA patients. In this group of patients we found a
highly significant correlation between the S-score and
the SHS reference score (P = 5.42 × 10−20, r2 (95 % confi-
dence interval (CI)) = 0.67 (0.57–0.75)), and therefore it
was considered an informative measure of joint damage.
IL6R tagging SNP selection
TagSNP identification for IL6R was performed using the
Tagger method implemented in Haploview software (v 4.2;
Broad Institute of MIT/Harvard University, Cambridge,
Massachussetts, USA). For this objective, the genotype data
from IL6R transcribed region (154,377,669–154,441,926
base pairs (bp) in chromosome 1) were analyzed, including
5000 bp flanking regions at the 5′ and 3′ ends of the gene.
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data from the Hapmap Caucasian European population
samples generated 1000 Genomes Project (1KG) were
used [10]. Within the IL6R coding region, a total of four
splice donor/acceptor variants, three stop gaining variants,
three frameshift variants, and 87 missense variants have
been identified in the IL6R sequence. Most of these vari-
ants, however, are rare (<1 % frequency) or have only been
identified at the single individual level (94.3 % variants).
Haplotype block analysis identified three main haplotype
blocks (Fig. 1a), with a relatively high linkage disequilibrium
(LD) between them (r2 >0.7). Pairwise tagging SNPs were
selected (minor allele frequency >0.05, pairwise r2 >0.8;
Additional file 1). TagSNPs tagging <2 SNPs were not se-
lected. A total of five tagSNPs were finally selected that
tagged 101 SNPs identified in the IL6R locus.SNP genotyping
Genomic DNA was isolated from venous blood sam-
ples obtained from RA patients using the Chemagic
Magnetic Separation Module I (PerkinElmer, Waltham,
Massachusetts, USA). SNP genotyping was performed
using the TaqMan® genotyping platform (Life Tech-
nologies, Carlsbad, California, USA). The TaqMan®
assays used to genotype IL-6R tagSNPs were:
C_____30047_10 (rs4845618), C__26292294_10 (rs4453032),
C__45267034_10 (rs4845374), C__11258914_10 (rs6698040),
and C__27968911_10 (rs4379670). Thermal cycle con-
ditions were as follows: 50 °C for 2 minutes and 95 °
C for 10 minutes, followed by 40 cycles of 92 °C for
15 seconds and 60 °C for 1 minute. All PCR and end-
point fluorescent readings were performed using an
ABI PRISM 7900 HT sequence detection system
(Life Technologies). The genotyping error was esti-
mated by genotyping 20 % of the samples in duplicate
(error <1 %).Statistical analysis
The association between IL6R tagging SNPs and joint
damage in RA was tested using linear regression with
an additive model. Using the linear modeling frame-
work allowed us to control for relevant covariates
such as age, years of disease duration, gender, anti-
citrullinated protein antibodies (ACPA) and rheumatoid
factor (RF) status. All statistical tests were performed
using the R statistical software version 3.0.1 [11]. Multiple
test correction was performed using the false discovery
rate (FDR) procedure.
The meta-analysis of the association results from the
discovery and replication cohorts was performed using
METAL software [12]. This method uses an inverse vari-
ance strategy to weight the association statistics according
to their effect size estimates (i.e., beta coefficients fromlinear regression) and their standard errors from the discov-
ery and validation cohorts of patients.
Haplotype analysis
IL6R haplotype blocks were defined using the model de-
scribed by Gabriel et al. [13]. Haplotypes were assigned
to each individual using PLINK software (version 1.07;
Center for Human Genetic Research (CHGR), Massa-
chusetts General Hospital (MGH), and the Broad Insti-
tute of Harvard and MIT, Boston, Massachusetts).
Analyses of the haplotypes were performed using the




A total of 527 RA patients were analyzed for association
between IL6R tag SNPs and joint destruction. We found
a highly significant association between SNP rs4845618
and the level of joint damage in the discovery cohort of
patients (P = 0.0052, β (95 % CI) = −1.09 (−0.33 to −1.85);
Table 1). This association was still significant after mul-
tiple testing correction (PFDR = 0.026). We also found a
significant association between SNP rs4845374 (P = 0.02,
β (95 % CI) = 1.14 (0.18–2.10); Table 1). After multiple test
correction this SNP was almost significant (PFDR = 0.050).
Both associated IL6R SNPs were in low LD between them
(r2 = 0.14).
An exploratory analysis using different genetic models
(i.e., genotypic, dominant, and recessive) did not find
strong evidence for an alternative genotype to phenotype
association for IL6R SNPs (Table S1 in Additional file 1).
Only under the dominant model was there a modest im-
provement over the original statistical significance for
the two SNPs rs4845618 and rs4845374. We also ex-
plored the influence of autoantibody status on the asso-
ciation of the five IL6R tagSNPs with joint damage
(Table S2 in Additional file 1). In this case, stratifying ac-
cording to ACPA or RF status did not increase the stat-
istical significance of IL6R SNPs with this disease
severity trait. Haplotype analysis using the two associ-
ated SNPs identified a significant association between
haplotypes GT and TA with the S-score (β = −1.12, P =
0.0037 and β = −1.28, P = 0.0099, respectively; Table 2).
Both haplotypes were significantly associated with joint
damage after multiple test correction (PFDR = 0.011 and
PFDR = 0.015 for GT and TA haplotypes, respectively).
Using all five tagSNPs to test for haplotype association,
we found less significant association. From the five esti-
mated haplotypes, only one showed a nominally signifi-
cant association (P = 0.019; Table 2). According to
these results only, the significant SNPs rs4845618 and
rs4845374 were tested in the independent patient
dataset.
Fig 1 (See legend on next page.)
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Fig 1 LD pattern at the IL6R locus. a Identification of the main haplotype blocks. Using Hapmap on 1000 Genomes Project data, we identified
two main haplotype blocks covering most of the IL6R sequence. The 5′ block covers an ~38 kb region (154,432,622–154,394,417 bp), and the
3′ block covers an ~6 kb IL6R sequence (154,432,877–154,439,865 bp). Using Haploview software (v 4.2; Broad Institute of MIT/Harvard University,
Cambridge, Massachussetts, USA), we searched for tagging SNPs within each haplotype block. b LD pattern associated with SNP rs4845618. LD (r2, y
axis) between SNPs in the IL6R locus and rs4845618 (purple diamond), the SNP most significantly associated with joint damage in RA. LD estimation
was obtained from Caucasian European data from Hapmap samples generated by the 1000 Genomes Project [10]. SNPs are colored according to
the LD level with rs4845618 (see legend). Markers with high LD (i.e. r2 >0.8) are mapped within the transcribed region of IL6R
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In the replication phase a total of 705 RA patients were
analyzed for validation of the association between IL6R
SNPs and the S-score. We significantly validated the asso-
ciation of both SNPs rs4845618 and rs4845374 (P = 0.007,
β (95 % CI) = −1.01 (−1.74 to −0.28), and P = 0.04, β (95 %
CI) = 0.95 (0.04–1.85), respectively) (Table 1). In both
SNPs, the direction of the effect (i.e., positive/negative β co-
efficient) was the same as in the discovery cohort. Both
polymorphisms were significantly associated with joint
damage after multiple test correction (PFDR = 0.014 and
PFDR = 0.040 for rs4845618 and rs4845374, respectively).
Haplotype analysis with the two validated SNPs repli-
cated the association between GT and TA haplotypes
with the S-score identified in the discovery phase (P =
0.0058 and P = 0.052, respectively; Table 2). In this case,
only GT haplotype association withstood multiple test
correction (PFDR = 0.017 and PFDR = 0.078 for GT and
TA haplotypes, respectively).
After performing the meta-analysis of the two SNPs
tested in both the discovery and replication datasets,
the statistical significance of the association of both
IL6R markers with joint damage was found to increase
(P = 0.00011 and P = 0.0021 for rs4845618 and rs4845374,
respectively) (Table 1). The association was strongest
when considering the two SNPs as a haplotype (GT haplo-
type, P = 0.0058, meta-analysis P = 6.65 × 10−8).Discussion
The key measure of severity in RA is the presence of
joint erosion as determined by radiological examination.Table 1 Association of IL6R locus SNPs with the severity of joint dam
Discovery phase
SNP Base pair Minor allele MAF βa (95 % CI)
rs4845618 154,400,015 G 0.44 −1.09 (−1.85 to −0.33)
rs4453032 154,414,086 G 0.40 0.25 (−0.51 to 1.01)
rs4845374 154,426,947 A 0.17 1.14 (0.18–2.10)
rs6698040 154,432,948 T 0.21 −0.79 (−1.75 to 0.17)
rs4379670 154,439,865 T 0.16 −0.64 (−1.72 to 0.44)
CI confidence interval, IL6R interleukin-6 receptor gene, MAF minor allele frequency
aCorrelation coefficient estimate, indicating the fold difference in joint damage in th
joint damage, positive coefficients indicate an increase of joint damage)
bP value estimated from the meta-analysis of the significance and effect sizes of disThe IL-6 signaling pathway is essential in the proinflam-
matory network that contributes to tissue destruction in
RA. Blocking a key member of this network, the IL-6 re-
ceptor has proven highly efficacious in the inhibition of
joint damage [5]. We have performed a candidate-gene
association study to test the association of genetic vari-
ation at IL6R with the level of erosions in RA.
To date, three main mRNA isoforms of IL6RA
have been described, with 10, 9 and 7 exons (mRNA iso-
forms 1, 2 and 3, respectively). We have found a strong
association between a SNP in the first intron common
to all isoforms and joint damage (SNP rs4845618,
P = 0.00011), and a moderate association of a SNP in
the sixth intron of isoforms 1 and 2 (rs4845374,
P = 0.0021). After combining both variants rs4845618
and rs4845374 as a haplotype, the association with the
level of joint damage in RA was found to be stronger
(P = 6.45 × 10−5). This result suggests that neither of
the two associated variants are the causal polymorph-
ism that influences joint destruction, and instead they
are proxies for another polymorphism. The LD pattern
associated with the most strongly associated SNP,
rs4845618, suggests that the causal polymorphism lies
within the transcribed sequence of IL6R (Fig. 1b). In
this region lies SNP rs2228145, a variant that was re-
cently found to have profound functional implications
in IL6R expression [14]. Importantly, this variant has
also been associated with RA risk [14, 15]. However,
the LD between rs4845374 and the SNP associated
with joint damage rs4845618 is moderate in the Cau-
casian European population, like our Spanish RA pa-
tient cohorts (r2 = 0.44; 1KG data). Furthermore, theage in RA
Replication phase
P value βa (95 % CI) P value Meta-analysis P valueb
0.0052 −1.01 (−1.74 to −0.28) 0.007 0.00011
0.51 – – –
0.02 0.95 (0.04–1.85) 0.04 0.0021
0.11 – – –
0.25 – – –
, RA rheumatoid arthritis, SNP single nucleotide polymorphism
e presence of the minor allele (i.e., negative coefficients indicate a decrease in
covery and replication cohorts
Table 2 Haplotype association results between IL6R locus SNPs with the severity of joint damage in RA
P valuec
Haplotypea SNPsb Discovery phase Replication phase
TA rs4845618|rs4845374 0.0099 0.052
GT rs4845618|rs4845374 0.0037 0.0058
TT rs4845618|rs4845374 0.38 0.023
GATTT rs4845618|rs4453032|rs4845374|rs6698040|rs4379670 0.31 –
GATTA rs4845618|rs4453032|rs4845374|rs6698040|rs4379670 0.14 –
TAACA rs4845618|rs4453032|rs4845374|rs6698040|rs4379670 0.02 –
TGTCA rs4845618|rs4453032|rs4845374|rs6698040|rs4379670 0.27 –
GATCA rs4845618|rs4453032|rs4845374|rs6698040|rs4379670 0.12 –
IL6R interleukin-6 receptor gene, RA rheumatoid arthritis, SNP single nucleotide polymorphism
aImputed haplotype according to the E–M algorithm implemented in PLINK (version 1.07; Center for Human Genetic Research (CHGR), Massachusetts General
Hospital (MGH), and the Broad Institute of Harvard and MIT, Boston, Massachusetts)
bList of IL6R tagSNPs used to estimate the haplotypes
cStatistical significance after testing the association of the estimated haplotype with the level of joint damage. Only haplotypes with a frequency >1 % were
tested for association
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showed no evidence of association with the level of
joint erosions in RA (P = 0.51; Table 1). These results
therefore suggest that the genetic variant associated with
joint erosions in RA is not the same variant associated
with disease risk. Future studies using next-generation se-
quencing analysis will be valuable to identify the precise
variation at the IL6R locus that increases the risk of
developing joint erosions at the IL6R locus.
In most human complex traits, the vast majority of
genetic associations are being identified outside coding
regions [16], and therefore the functional link is gener-
ally difficult to identify. In the present study, the SNP
showing the strongest association to joint damage,
rs4845618, is an intronic SNP of IL6R. Evaluating pub-
licly available results on tissue expression quantitative
loci (eQTL) analysis [17], there is evidence supporting
rs4845618 being a highly significant cis-eQTL for IL6R
expression in whole blood (P = 1.1 × 10−16; data not
shown). Also, analyzing the most recent regulatory and
epigenetic evidence generated from large international
consortia such as the Roadmap Epigenomics project [18],
there is strong regulatory evidence associated with this
SNP (Table S3 in Additional file 1). In particular, the
rs4845618 SNP region is associated with regulatory activ-
ity in more than 50 different human cell types, including
CD4+ T cells. Together these results support the present
genetic association with joint damage being likely to influ-
ence IL6R regulatory activity.
Tocilizumab is a monoclonal antibody against IL6R,
prevents downstream IL-6 signaling and has been shown
to significantly reduce the signs and symptoms of RA. In
particular, there is increasing evidence that IL6R blockade
prevents structural joint damage [19]. IL-6 is a pleiotropic
inflammatory cytokine and therefore many biological
mechanisms can explain the efficacy of this treatment [3].From these mechanisms, the inhibition of inflammatory
osteoclastogenesis after IL6R blocking [20] is clearly the
most direct biological process influencing the level of joint
destruction in RA. There is recent suggestive evidence
that variants at IL6R are associated with the clinical
response to tocilizumab [21]. While these results are
still preliminary, they provide additional support for
the importance of variation at this gene with disease
proinflammatory activity. Future studies analyzing the
association between SNPs in the present study with
the response to tocilizumab are possible.
In the present study we prioritized the selection of the
best tagging SNPs of IL6R variation over previously pub-
lished variants, in order to capture most of the common
variation in this gene. For example, IL6R SNP rs8192284
(now merged into SNP rs2228145) – which had been
previously associated with disease activity in RA [22] –
was not selected for genotyping. Importantly, however,
rs8192284 is in very high LD with the genotyped SNP
rs4453032 (r2 = 0.91, 1000 Genomes Project data on a
Caucasian European population). As shown in the discov-
ery stage, there is no evidence for association between
SNP rs4453032 and joint damage in RA (P = 0.51; Table 1).
The high LD between rs8192284 and rs4453032 therefore
supports the lack of association of this variant with joint
damage in RA. This result confirms that the objective se-
lection of the most informative markers is a powerful ap-
proach to identify the relevant genetic variation associated
with disease severity in RA.
One potential limitation of this study is that using a
simplified score might have reduced the statistical power
of the association. It is possible that using a more stand-
ard score such as the SHS we would have better assessed
joint damage in the RA cohorts, and therefore found a
more significant association with the genetic variation at
the IL6R locus. Nonetheless, the significant association
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validation cohort strongly supports the usefulness of the
S-score to capture the essential features of this trait in
RA. While the loss of information from not using a ref-
erence score like SHS would be unacceptable in clinical
studies such as treatment efficacy analysis, this simplified
erosion score could be a practical tool in those instances
like genetic studies in which a large number of patient
data must be collected from multiple centers and there
is no possibility to perform more complex scores of joint
damage.
Conclusions
In this study we have identified and replicated variation
at IL6R associated with the level of joint damage in RA.
Further functional studies at the transcriptional and pro-
tein level are needed to characterize the precise molecular
mechanism influenced by this genetic variation.
Additional file
Additional file 1: Table S1. Presenting the association of IL6R locus
SNPs with joint damage in the discovery stage under alternative genetic
models, Table S2. Presenting the association of IL6R locus SNPs with
joint damage in the discovery stage according to ACPA or RF status, and
Table S3. Presenting the enhancer histone marks associated with the
IL6R rs4845618 SNP identified in 111 reference epigenomes from the
Epigenome Roadmap Project.
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